Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 27, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 31, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference .
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin ® ; Initial Data from Expansion Cohort in Combination with Keytruda ® to be Presented at ESMO $163 Million Net Proceeds from Public
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 12, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second
View HTML
Toggle Summary ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full
View HTML
Toggle Summary ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 18, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for its lead
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 30, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
View HTML